In silico investigation of the effect of particle diameter on deposition uniformity in pulmonary drug delivery

Abstract Systemic drug delivery via the pulmonary route has a critical limitation because dose uniformity is strongly dependent upon patient inhalation technique. The most frequent and critical errors in inhalation technique are overly forceful inspiration and insufficient breath-holding. In this study, response surface methodology was used with an in silico whole lung particle deposition model for bolus administration to investigate whether varying the inhaled drug particle size could reduce the dependence of deposition upon flow rate and/or breath-holding duration. The range of particle aerodynamic diameters studied was 0.1–10 µm for flow rates between 500–2000 mL/s and breath-holding duration between 0–15 seconds. Comparison with published experimental data showed that this modeling approach can accurately predict the lung deposition. The simulation results indicated that the deposition of particles with aerodynamic diameter in the range of 0.1–1.5 µm should be minimally affected by flow rate over the 500–2000 mL/s range. There was found to be no particle size whose deposition was completely independent of breath-holding duration. The smallest particles, whose deposition is diffusion-driven, were found to be the least sensitive to breath-holding time, but this size is of limited practical use. On the other hand, the simulations indicated that particles with a 1.5 µm diameter would provide acceptable consistency in dose reaching the acini region when the breath-holding duration was greater than 10 seconds. It is hoped that this finding could provide a means of improving dose uniformity for systemic delivery via the pulmonary route by facilitating simplified patient instructions.

[1]  G. Scheuch,et al.  Regional Lung Deposition: In Vivo Data. , 2020, Journal of aerosol medicine and pulmonary drug delivery.

[2]  J. Khinast,et al.  Estimating inter-patient variability of dispersion in dry powder inhalers using CFD-DEM simulations. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  Qihong Deng,et al.  Particle Deposition in Human Lung Airways: Effects of Airflow, Particle Size, and Mechanisms , 2020 .

[4]  M. Sakagami In vitro, ex vivo and in vivo methods of lung absorption for inhaled drugs. , 2020, Advanced drug delivery reviews.

[5]  C. Darquenne Deposition Mechanisms. , 2020, Journal of Aerosol Medicine.

[6]  E. Matida,et al.  Experimental Study of Spiriva Respimat Soft Mist Inhaler Spray Characterization: Size Distributions and Velocity. , 2019, Journal of aerosol medicine and pulmonary drug delivery.

[7]  Runyu Yang,et al.  CFD modelling of air and particle flows in different airway models , 2019, Journal of Aerosol Science.

[8]  Yatin R. Gokarn,et al.  Non-invasive delivery strategies for biologics , 2018, Nature Reviews Drug Discovery.

[9]  S. Newman Drug delivery to the lungs: challenges and opportunities. , 2017, Therapeutic delivery.

[10]  Clement Kleinstreuer,et al.  Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application , 2017, Comput. Biol. Medicine.

[11]  Georges Caillibotte,et al.  The Creation and Statistical Evaluation of a Deterministic Model of the Human Bronchial Tree from HRCT Images , 2016, PloS one.

[12]  A. Melikov,et al.  Particle deposition in a realistic geometry of the human conducting airways: Effects of inlet velocity profile, inhalation flowrate and electrostatic charge. , 2016, Journal of biomechanics.

[13]  Andrew R. Martin,et al.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung. , 2016, Journal of aerosol medicine and pulmonary drug delivery.

[14]  C. Kloft,et al.  Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs , 2015, The AAPS Journal.

[15]  Lawrence X. Yu,et al.  International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences , 2015, The AAPS Journal.

[16]  D. Klonoff Afrezza Inhaled Insulin , 2014, Journal of diabetes science and technology.

[17]  Joy Conway,et al.  Airway Morphology From High Resolution Computed Tomography in Healthy Subjects and Patients With Moderate Persistent Asthma , 2013, Anatomical record.

[18]  R. Narayanacharyulu,et al.  In-Vitro, Ex-Vivo and In-Vivo Evaluation of Transdermal Delivery of Felodipine , 2013 .

[19]  W. Finlay,et al.  An In vitro Study on the Deposition of Micrometer-Sized Particles in the Extrathoracic Airways of Adults During Tidal Oral Breathing , 2013, Annals of Biomedical Engineering.

[20]  H. Smyth,et al.  Controlled Pulmonary Drug Delivery , 2011 .

[21]  Jiyuan Tu,et al.  Micron particle deposition in a tracheobronchial airway model under different breathing conditions. , 2010, Medical engineering & physics.

[22]  G. Prisk,et al.  Alveolar duct expansion greatly enhances aerosol deposition: a three-dimensional computational fluid dynamics study , 2009, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[23]  Peter Brand,et al.  Higher lung deposition with Respimat® Soft Mist™ Inhaler than HFA-MDI in COPD patients with poor technique , 2008, International journal of chronic obstructive pulmonary disease.

[24]  R. Sturm,et al.  Semi-Empirical Stochastic Model of Aerosol Bolus Dispersion in the Human Lung , 2008 .

[25]  O. Usmani,et al.  Regional Lung Deposition and Bronchodilator Response as a Function of β2-Agonist Particle Size , 2005 .

[26]  Douglas R. Worsnop,et al.  Particle Morphology and Density Characterization by Combined Mobility and Aerodynamic Diameter Measurements. Part 1: Theory , 2004 .

[27]  Stephen P. Newman,et al.  Improved Lung Delivery from a Passive Dry Powder Inhaler Using an Engineered PulmoSphere® Powder , 2002, Pharmaceutical Research.

[28]  W. Hofmann,et al.  Particle Deposition in a Multiple-Path Model of the Human Lung , 2001 .

[29]  R. Hermann,et al.  Scintigraphic comparison of budesonide deposition from two dry powder inhalers. , 2000, The European respiratory journal.

[30]  J. Heyder,et al.  Total deposition of therapeutic particles during spontaneous and controlled inhalations. , 2000, Journal of pharmaceutical sciences.

[31]  J. Heyder,et al.  Aerosol bolus dispersion in healthy subjects. , 1997, The European respiratory journal.

[32]  D. Taylor,et al.  Human Respiratory Tract Model for Radiological Protection , 1996 .

[33]  B. Asgharian,et al.  A multiple-path model of particle deposition in the rat lung. , 1995, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[34]  C. P. Yu Exact analysis of aerosol deposition during steady breathing , 1978 .

[35]  Otto G. Raabe,et al.  Tracheobronchial Geometry: Human, Dog, Rat, Hamster - A Compilation of Selected Data from the Project Respiratory Tract Deposition Models , 1976 .

[36]  D. Ingham Diffusion of aerosols from a stream flowing through a cylindrical tube , 1975 .

[37]  J. Beeckmans THE DEPOSITION OF AEROSOLS IN THE RESPIRATORY TRACT. I. MATHEMATICAL ANALYSIS AND COMPARISON WITH EXPERIMENTAL DATA. , 1966, Canadian journal of physiology and pharmacology.

[38]  Margaret J. Robertson,et al.  Design and Analysis of Experiments , 2006, Handbook of statistics.

[39]  H. Landahl On the removal of air-borne droplets by the human respiratory tract: I. The lung , 1950 .

[40]  Wenqi Zhong,et al.  Numerical investigation of particle deposition in a triple bifurcation airway due to gravitational sedimentation and inertial impaction , 2018 .

[41]  Yung-sung Cheng,et al.  Deposition of Particles in Human Mouth-Throat Replicas and a USP Induction Port. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[42]  Bo Olsson,et al.  Pulmonary Drug Metabolism, Clearance, and Absorption , 2011 .

[43]  Jinxiang Xi,et al.  Computational investigation of particle inertia effects on submicron aerosol deposition in the respiratory tract , 2007 .

[44]  Dale Farris,et al.  Design of Experiments With MiNITAB , 2005 .

[45]  J. Patton,et al.  The lungs as a portal of entry for systemic drug delivery. , 2004, Proceedings of the American Thoracic Society.

[46]  L. Borgström,et al.  Lung deposition of budesonide inhaled via Turbuhaler: a comparison with terbutaline sulphate in normal subjects. , 1994, The European respiratory journal.

[47]  J. Heyder,et al.  Deposition of particles in the human respiratory tract in the size range 0.005–15 μm , 1986 .

[48]  A. Black,et al.  Regional deposition of 2.5-7.5 μm diameter inhaled particles in healthy male non-smokers , 1978 .